Replies to post #228146 on Biotech Values

[DewDiligence]

Re: Amended BMY-NKTR deal

Cost/profit sharing scheme (in Amendment) did not change, so BMY can do *on its own* as it pleases.

What’s notable (IMO) about the new dosing study in NSCLC is not that BMY is permitted to conduct and fund the trial independently, but rather that BMY thinks this trial is needed while NKTR evidently does not think it is needed. Why the disparity?

…NKTR can not continue with Pembro NSCLC combination until 4/2021. (If I am correct here?)

Correct if the word, “develop” means (inter alia) conducting a clinical trial, which is the usual definition in these kinds of contracts.

Do we even know that MRK still wants to participate in a Keytruda + bempeg trial in NSCLC?